Literature DB >> 30254188

Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data.

Ryota Tanaka1,2,3, Kan Yonemori4, Akihiro Hirakawa5, Fumie Kinoshita6, Yumiko Kobayashi6, Naoya Yamazaki2, Manabu Fujimoto3, Kenji Tamura1, Yasuhiro Fujiwara1.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are potentially life-threatening cutaneous and mucosal adverse reactions to drugs. Nevertheless, the connection to anticancer agents remains unclear. To provide insight into the association of such adverse reactions with anticancer agents, we analyzed the profile of anticancer agent-induced SJS and TEN in the Japanese population. Of the 9,738 SJS/TEN events recorded in a database of spontaneous reporting data, 485 (5%, further categorized as SJS, 384 events, 79%; TEN, 101 events, 21%) were identified as anticancer agent-induced, and 53 of these (11%) were fatal. Multivariate logistic regression analyses indicated that, compared with patients using other drugs, those using anticancer drugs had lower incident risk of death (hazard ratio [HR], 0.592; p = .0006), longer median time to onset of SJS/TEN (18 vs. 11 days; p < .0001; multivariate Cox regression: HR, 0.66; p < .0001), and a higher likelihood of developing SJS/TEN later than 70 days after initiation of the suspected causal agent (15% vs. 7%; p < .0001), highlighting the need for vigilance and continuous monitoring for SJS/TEN in patients treated with anticancer agents. IMPLICATIONS FOR PRACTICE: Life-threatening skin toxicities induced by anti-cancer agents indicated significantly lower incident risk of death and longer time to onset of symptoms than for those induced by other drugs. © AlphaMed Press 2018.

Entities:  

Keywords:  Cancer; Skin toxicity; Stevens‐Johnson syndrome; Toxic epidermal necrolysis; Treatment

Year:  2018        PMID: 30254188      PMCID: PMC6369946          DOI: 10.1634/theoncologist.2017-0511

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  26 in total

1.  Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.

Authors:  Megumi Hori; Tomohiro Matsuda; Akiko Shibata; Kota Katanoda; Tomotaka Sobue; Hiroshi Nishimoto
Journal:  Jpn J Clin Oncol       Date:  2015-07-03       Impact factor: 3.019

Review 2.  Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up.

Authors:  H Y Lee; S A Walsh; D Creamer
Journal:  Br J Dermatol       Date:  2017-09-22       Impact factor: 9.302

3.  Epidemiology of cutaneous adverse drug reactions.

Authors:  Maja Mockenhaupt
Journal:  Chem Immunol Allergy       Date:  2012-05-03

4.  How does older age influence oncologists' cancer management?

Authors:  Jill A Foster; Gregory D Salinas; Dorcas Mansell; James C Williamson; Linda L Casebeer
Journal:  Oncologist       Date:  2010-05-23

5.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Peggy Sekula; Ariane Dunant; Maja Mockenhaupt; Luigi Naldi; Jan Nico Bouwes Bavinck; Sima Halevy; Sylvia Kardaun; Alexis Sidoroff; Yvonne Liss; Martin Schumacher; Jean-Claude Roujeau
Journal:  J Invest Dermatol       Date:  2013-02-07       Impact factor: 8.551

6.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.

Authors:  Ariane Auquier-Dunant; Maja Mockenhaupt; Luigi Naldi; Osvaldo Correia; Werner Schröder; Jean-Claude Roujeau
Journal:  Arch Dermatol       Date:  2002-08

7.  Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.

Authors:  B N Stein; N J Petrelli; H O Douglass; D L Driscoll; G Arcangeli; N J Meropol
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

8.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

Authors:  Maja Mockenhaupt; Cecile Viboud; Ariane Dunant; Luigi Naldi; Sima Halevy; Jan Nico Bouwes Bavinck; Alexis Sidoroff; Jürgen Schneck; Jean-Claude Roujeau; Antoine Flahault
Journal:  J Invest Dermatol       Date:  2007-09-06       Impact factor: 8.551

Review 9.  Drug-induced severe skin reactions. Incidence, management and prevention.

Authors:  P Wolkenstein; J Revuz
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

10.  Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults.

Authors:  Derek Y Hsu; Joaquin Brieva; Nanette B Silverberg; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2016-03-30       Impact factor: 8.551

View more
  2 in total

1.  Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System.

Authors:  Emanuel Raschi; Ippazio Cosimo Antonazzo; Michelangelo La Placa; Andrea Ardizzoni; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Oncologist       Date:  2019-08-06

2.  Homoharringtonine Inhibits Allergic Inflammations by Regulating NF-κB-miR-183-5p-BTG1 Axis.

Authors:  Misun Kim; Hyein Jo; Yoojung Kwon; Youngmi Kim; Hyun Suk Jung; Dooil Jeoung
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.